

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<i>In re</i> Application of:)	
)	Group Art Unit: TBA
Ching-Hsiang Hsu)	
)	Examiner: TBA
Serial No.: TBA)	
)	
Filed: January 5, 2004)	
)	
For: PROCESS FOR PRODUCING DUST MITE)	
ALLERGEN)	Docket No. 001409.00008

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Post Office Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Submitted herewith is one (1) sheet of Form PTO-1449 and a copy of each of the documents listed therein. It is respectfully requested that the Examiner make his/her consideration of each of these documents formally of record.


Since this Information Disclosure Statement is being filed contemporaneously with the application, it is submitted that no fee or certification is required. However, if a fee is required, please charge our deposit account no. 19-0733.

Respectfully submitted,

BANNER & WITCOFF, LTD.

Dated: January 5, 2004

By:



Sarah A. Kagan

Registration No. 32,141

Customer No. 22907

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	TBA
		Filing Date	January 5, 2004
		First Named Inventor	Ching-Hsiang Hsu
		Group Art Unit	TBA
		Examiner Name	TBA
Sheet 1 of 1	Attorney Docket Number	001409.00008	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Weiner, H. L., "Oral tolerance: immune mechanisms and treatment of autoimmune diseases." Immunology Today 1997;18:335-42.	
		Friedman A. and Weiner, H. L., "Induction of anergy or active suppression following oral tolerance is determined by antigen dosage." Proc Natl Acad Sci USA 1994;91:6688-92.	
		Passalacqua G. et al., "Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis." Lancet 1998;351:629-32.	
		Marth T. et al., "High dose oral tolerance in ovalbumin TCR-transgenic mice." The Journal of Immunology 1996;157:2348-57.	
		Gütgemann I. et al., "Induction of rapid T cell activation and tolerance by systemic presentation of an orally administered antigen." Immunity 1998;8:667-73.	
		Mason, H. S. et al., "Expression of hepatitis B surface antigen in transgenic plants." Proc. Natl. Acad. Sci. 1992 89:11745-11749.	
		Carrillo, C. et al., "Protective immune response to foot-and-mouth disease virus with VP1 expressed in transgenic plants." Journal of Virology 1998 72:1688-1690.	
		Gilleland H. E. Jr. et al., "Chimeric animal and plant viruses expressing epitopes of outer membrane protein F as a combined vaccine against Pseudomonas aeruginosa lung infection." FEMS Immunology and Medical Microbiology. 2000 27:291-297.	
		Gal-On A. et al., "Characterisation of genetically modified cucumber mosaic virus expressing histidine-tagged 1a and 2a proteins." Arch Virol 2000;145(1):37-50.	
		Lin, S. S. et al., "Construction of in vitro and in vivo infectious transcripts of a Taiwan strain of Zucchini yellow mosaic virus." Bot. Bull. Acad. Sin. 2002;43:261-269.	
		Hsu, C. H. et al. "Immunoprophylaxis of allergen-induced IgE synthesis and airway hyperresponsiveness in vivo by genetic immunization." Nature Medicine 1996;2:540-4.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.